Jacobs Levy Equity Management Inc. Reduces Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)

Jacobs Levy Equity Management Inc. reduced its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 41.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 280,271 shares of the company's stock after selling 195,987 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.50% of Design Therapeutics worth $1,508,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp raised its position in shares of Design Therapeutics by 2.5% in the second quarter. Bank of New York Mellon Corp now owns 118,110 shares of the company's stock worth $396,000 after acquiring an additional 2,868 shares during the period. Palumbo Wealth Management LLC raised its holdings in shares of Design Therapeutics by 11.3% in the 3rd quarter. Palumbo Wealth Management LLC now owns 36,774 shares of the company's stock valued at $198,000 after buying an additional 3,720 shares during the period. PDT Partners LLC lifted its position in shares of Design Therapeutics by 33.1% during the third quarter. PDT Partners LLC now owns 36,099 shares of the company's stock worth $194,000 after purchasing an additional 8,972 shares in the last quarter. Walleye Capital LLC raised its stake in shares of Design Therapeutics by 16.3% in the third quarter. Walleye Capital LLC now owns 70,000 shares of the company's stock valued at $377,000 after acquiring an additional 9,788 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Design Therapeutics by 75.6% during the second quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company's stock worth $79,000 after purchasing an additional 10,113 shares in the last quarter. Institutional investors own 56.64% of the company's stock.

Design Therapeutics Price Performance

Shares of NASDAQ:DSGN traded up $0.09 during trading on Monday, hitting $6.50. 52,932 shares of the company were exchanged, compared to its average volume of 233,724. The firm's 50 day moving average price is $5.63 and its 200-day moving average price is $4.84. Design Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $7.77. The stock has a market capitalization of $368.03 million, a P/E ratio of -7.54 and a beta of 1.86.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.